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Background: Atrial fibrillation (AF) is the most common dysrhythmia in the U.S. and 
Europe. Few biomarkers exist to identify individuals at risk for AF. Cardiac microRNAs 
(miRNAs) have been implicated in susceptibility to AF and are detectable in the 
circulation. Nevertheless, data are limited on how circulating levels of miRNAs relate to 
AF or change over time after catheter- ablation. 
Methods: In 211 miRhythm participants (112 with paroxysmal or persistent AF; 99 
without AF), we quantified plasma expression of 86 miRNAs associated with cardiac 
remodeling or disease by high-throughput quantitative reverse-transcriptase polymerase 
chain reaction (qRT-PCR). We used qRT-PCR to examine change in plasma miRNA 
expression from baseline to 1-month after ablation in 47 participants. We also quantified 
expression of the 20 most variable miRNAs in atrial tissue in 31 participants undergoing 
cardiac surgery. 
Results: The mean age of the miRhythm cohort was 59 years and 58% of participants 
were men. 21 miRNAs differed significantly between participants with AF and those with 
no AF in regression models adjusting for known AF risk factors (p value of ≤ 0.0006). 
Several miRNAs associated with AF, including miR-21, miR-29a, miR-122, miR-150, 
miR-320, and miR-92a, regulate expression of genes implicated in the pathogenesis of 
AF. Levels of 33 miRNAs, including 14 associated with AF, changed significantly 
between baseline and 1-month after catheter ablation (p value of ≤ 0.0006). Although all 
AF-related plasma miRNAs were expressed in atrial tissue, only miR-21 and miR-411 
differed significantly with respect to preoperative AF status. 
Conclusions: Plasma levels of miRNAs associated with heart disease and cardiac 
remodeling were related to AF and changed after catheter-ablation. Our study suggests 
that AF has a unique circulating miRNA profile and that this profile is influenced by 
catheter-ablation.  
